What’s the current market cap for Cabaletta Bio stock?

Cabaletta Bio (CABA) has a market cap of $607M as of May 27, 2026.

What is the P/E ratio for Cabaletta Bio stock?

The price to earnings (P/E) ratio for Cabaletta Bio (CABA) stock is 0 as of May 27, 2026.

Does Cabaletta Bio stock pay dividends?

No, Cabaletta Bio (CABA) stock does not pay dividends to its shareholders as of May 27, 2026.

When is the next Cabaletta Bio dividend payment date?

Cabaletta Bio (CABA) stock does not pay dividends to its shareholders.

What is the beta indicator for Cabaletta Bio?

Cabaletta Bio (CABA) has a beta rating of 3.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Cabaletta Bio stock | $CABA Share Price

13:30

15:10

16:45

18:25

20:00

About Cabaletta Bio

Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Ticker

$CABA

Sector

Health

Primary listing

NASDAQ

Employees

155

Headquarters

Philadelphia, United States

Website

www.cabalettabio.com

Cabaletta Bio Metrics

BasicAdvanced

$607m

-$1.84

3.17

What the Analysts think about Cabaletta Bio

Analyst ratings (Buy, Hold, Sell) for Cabaletta Bio stock.

Bulls say / Bears say

Cabaletta’s RESET-PV trial reported April 2, 2026 data showing complete B-cell depletion in 3 of 4 refractory pemphigus vulgaris patients, with three of them treatment-free and only one case of Grade 1 cytokine release syndrome, supporting moving to higher dose groups. (Reuters)

The company raised $150 million through an underwritten equity offering at $2.90 per share, with investors such as Bain Capital, Adage Capital Management, Cormorant, and Eli Lilly, extending its cash runway into mid-2027. (Reuters)

Cabaletta signed a 10-year commercial supply deal with Cellares to automate and scale up rese-cel manufacturing, making it possible to produce thousands of batches per year more cost-effectively. (Reuters)

The $2.90 per share offering added 51.7 million new shares to the 100.5 million already outstanding, leading to about 44 percent dilution for current shareholders. (SEC filing)

The RESET-PV trial's early clinical results are based on just four patients, with sustained six-month responses seen in only two, making it unclear if results can be repeated in larger groups. (Reuters)

Management cautioned that future fundraising depends on trial progress and there is no set plan for raising more capital after mid-2027, which could mean further dilution for investors. (SEC filing)

Data summarised monthly by Lightyear AI. Last updated on 6 May 2026.

Cabaletta Bio Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Cabaletta Bio Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CABA

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

The $2.90 per share offering added 51.7 million new shares to the 100.5 million already outstanding, leading to about 44 percent dilution for current shareholders. (SEC filing)

Management cautioned that future fundraising depends on trial progress and there is no set plan for raising more capital after mid-2027, which could mean further dilution for investors. (SEC filing)

Data summarised monthly by Lightyear AI. Last updated on 6 May 2026.